[
    {
        "content": "* Says \u200dlaunch of clofarabine injection in U.S. market\u200b Source text: http://bit.ly/2zBoR7i Further company coverage:",
        "date": "11142017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Labs \u200dlaunches clofarabine injection in U.S. "
    },
    {
        "content": "* DR REDDY'S LABORATORIES ANNOUNCES THE LAUNCH OF GENERIC AZACITIDINE FOR INJECTION IN THE CANADIAN MARKET",
        "date": "11022017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-DR. REDDY'S LABORATORIES LAUNCHES GENERIC AZACITIDINE FOR INJECTION IN CANADIAN MARKET "
    },
    {
        "content": "* Sept quarter consol net profit after tax 3.05 billion rupees versus 3.09 billion rupees last year",
        "date": "10312017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-India's Dr.Reddy's Laboratories Sept-qtr consol PAT down about 1 pct "
    },
    {
        "content": "* \u200dSTARTS COOPERATION WITH DR. REDDY'S LABORATORIES ON SALES IN NORTH AMERICA\u200b Source text for Eikon: Further company coverage: (Gdynia Newsroom)",
        "date": "10122017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Enorama Pharma \u200dstarts cooperation with Dr. Reddy's Laboratories "
    },
    {
        "content": "* Says gets EIR from U.S. FDA for formulation Srikakulam plant (SEZ) unit 1  Andhra Pradesh Source text - http://bit.ly/2wleXS9 Further company coverage:",
        "date": "09282017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Labs gets EIR from U.S. FDA for plant in Andhra Pradesh "
    },
    {
        "content": "* FDA completes \u200daudit of co's Telangana custom pharmaceutical services facility  technology development centre with no observations\u200b Source text: http://bit.ly/2hhsmbf Further company coverage:",
        "date": "09212017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Labs says FDA completes \u200daudit of co's Telangana facilities with no observations\u200b "
    },
    {
        "content": "* Says received an establishment inspection report (EIR) from US FDA for formulation Srikakulam plant Source text for Eikon: Further company coverage:",
        "date": "09212017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "normal",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Laboratories gets EIR from US FDA for Formulation Srikakulam plant "
    },
    {
        "content": "Sept 15 Indivior's U.S. subsidiary has filed lawsuits against firms seeking approval for generic versions of its opioid addiction treatment Suboxone  which generates 80 percent of the drugmaker's revenue.",
        "date": "09152017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "normal",
        "symbol": "RDY",
        "title": "UPDATE 1-Indivior files lawsuits against Suboxone generic rivals "
    },
    {
        "content": "* Says Aurigene Discovery Technologies  Curis plan to initiate phase 2 trial of CA-170 in India\u200d\u200b",
        "date": "09122017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Labs' Aurigene  Curis to start mid-stage study of CA-170 "
    },
    {
        "content": "* Says announces launch of bupropion hydrochloride extended-release tablets  USP (XL) in U.S. Market",
        "date": "09062017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr. Reddy's Laboratories announces launch of two drugs in U.S. market "
    },
    {
        "content": "Sept 8 Dr. Reddy's Laboratories said on Friday a German regulator has made six major observations about its Duvvada drug making facility in the southern Indian state of Andhra Pradesh  sending shares down as much as 7.1 percent.",
        "date": "09082017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "India's Dr Reddy's says German regulator makes 6 observations on unit "
    },
    {
        "content": "* Regulatory Authority of Germany concluded audit of formulations manufacturing facility in Vishakapatnam",
        "date": "09082017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "normal",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Laboratories says Regulatory Authority of Germany concludes audit of facility "
    },
    {
        "content": "* Vivus announces settlement with Dr. Reddy's laboratories on qsymia(r) patent litigation",
        "date": "08302017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Vivus reports settlement with Dr. Reddy's laboratories on qsymia patent litigation "
    },
    {
        "content": "* Dr Reddys welcomes ruling (Adds Dr Reddy's comment  further reaction)",
        "date": "09012017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "UPDATE 3-London-listed drugmaker Indivior shares crash after U.S. patent blow "
    },
    {
        "content": "* Dr.Reddy's Laboratories clarifies on news item regarding settling patent row with vivus",
        "date": "09012017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "normal",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Labs says overall impact on financials of settlement disputes with Vivus not likely to be material "
    },
    {
        "content": "* U.S. court ruling in favour of co on generic version of suboxone doesn't infringe U.S. patents as asserted by Indivior Source text - http://bit.ly/2eo6WEQ Further company coverage:",
        "date": "09012017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "normal",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Labs says ruling in favour of co on generic version of Suboxone doesn't infringe U.S. patents as asserted by Indivior "
    },
    {
        "content": "Sept 1 Indivior said on Friday it would appeal against a U.S. court ruling that generic drug maker Dr Reddy's had not infringed its patents  potentially opening the way to a rival to the firm's Suboxone Film opiod addiction treatment.",
        "date": "09012017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "normal",
        "symbol": "RDY",
        "title": "UK drug firm Indivior to appeal U.S ruling on Dr Reddy's generic drug "
    },
    {
        "content": "* Says launch of Cefixime for oral suspension  usp in U.S. Market Source text for Eikon: Further company coverage:",
        "date": "08282017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Laboratories launches Cefixime for oral suspension  usp in the U.S. "
    },
    {
        "content": "* Says co \u200dannounces out-licensing of DFD-06 to Encore Dermatology\u200b",
        "date": "08222017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Labs unit out-licenses psoriasis drug to Encore Dermatology\u200b "
    },
    {
        "content": "* \u200dGMP compliance certificate relating to co's manufacturing unit in Hyderabad not renewed consequent to recent inspection of plant\u200b",
        "date": "08102017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Labs says \u200dGMP compliance certificate relating to Hyderabad unit not renewed "
    },
    {
        "content": "July 28 India's NSE index took a breather on Friday after hitting record highs in each of the previous four sessions  as disappointing quarterly earnings weighed on bank and pharmaceutical shares.",
        "date": "07282017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "Indian shares decline; Dr. Reddy's  ICICI Bank fall on weak Q1 "
    },
    {
        "content": "* COO Abhijit Mukherjee says expects adverse pricing environment in U.S. to persist",
        "date": "07272017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-India's Dr Reddy's expects U.S. \"adverse pricing environment\" to persist "
    },
    {
        "content": "* Co  CHD Bioscience announce global license & commercialization deal for phase III clinical trial candidate for mitigation of surgical site infections",
        "date": "07272017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "normal",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Laboratories  CHD Bioscience announce global license & commercialization deal "
    },
    {
        "content": "* North America generics business revenue down 4 percent (Adds details  CEO comment  background)",
        "date": "07272017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "normal",
        "symbol": "RDY",
        "title": "UPDATE 1-India's Dr Reddy's Q1 profit slumps on pricing pressures in U.S. "
    },
    {
        "content": "* June quarter consol net profit after tax and share of profit of associates  666 million rupees versus profit of 1.54 billion rupees last year",
        "date": "07272017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "normal",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Laboratories June-qtr consol profit falls about 57 pct "
    },
    {
        "content": "July 27 Dr.Reddy's Laboratories Ltd reported a 57 percent slump in its first-quarter profit as regulatory hurdles and pricing pressures in its biggest market  the United States  dragged on the drugmaker's earnings.",
        "date": "07272017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "normal",
        "symbol": "RDY",
        "title": "India's Dr Reddy's Q1 profit slumps 57 pct y/y "
    },
    {
        "content": "* Says audit of our API Cuernavaca plant at Mexico  by US FDA  has been completed with zero observations Source text for Eikon: Further company coverage:",
        "date": "07212017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Labs says audit of Mexican plant by USFDA completed with zero observations "
    },
    {
        "content": "* Says formulations Srikakulam Plant (SEZ) unit I  Andhra Pradesh  by US FDA  has been completed Friday",
        "date": "06162017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr. Reddy's Lab says USFDA issues form 483 with one observation for Srikakulam Plant "
    },
    {
        "content": "* Dr.Reddy's Laboratories clarifies on news item  \"Dr Reddy's recalls 3.25l cartons Cipla-made acne drug from US\".",
        "date": "06152017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Labs recalls Cipla-made zenatane capsule from U.S. markets "
    },
    {
        "content": "* Says got EIR after audit of API manufacturing plant at Miryalaguda  by US FDA   as closure of audit Source text - (http://bit.ly/2smE0VK) Further company coverage:",
        "date": "06142017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Labs gets EIR as closure of audit of Miryalaguda API manufacturing plant "
    },
    {
        "content": "* Says announces launch of Bivalirudin for injection in U.S. market Source text for Eikon: Further company coverage:",
        "date": "06062017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Laboratories announces launch of Bivalirudin for injection in U.S. market "
    },
    {
        "content": "* Says audit of formulations Srikakulum Plant unit II  Andhra Pradesh by US FDA  completed with zero observations. Source text - (http://bit.ly/2qnkt2M) Further company coverage:",
        "date": "05252017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Labs' audit of formulations Srikakulum plant Unit II completed with zero observations "
    },
    {
        "content": "* Announces USFDA approval for launch of doxorubicin hydrochloride liposome injection in U.S. Market Source text - (http://bit.ly/2qQ6RC6) Further company coverage:",
        "date": "05172017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Laboratories says USFDA approved launch of doxorubicin hydrochloride liposome injection in U.S. "
    },
    {
        "content": "* Consensus forecast for March quarter consol profit was 4.27 billion rupees",
        "date": "05122017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-India's Dr.Reddy's Laboratories March-qtr consol profit rises about three-fold "
    },
    {
        "content": "* Fresenius ceo sturm says we've had a good q1 but will not provide details",
        "date": "04252017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Fresenius sees no change in relationship of Merck KGaA's unit with partner Dr Reddy's "
    },
    {
        "content": "* Says launch of Ezetimibe and Simvastatin tablets in U.S. market Source text for Eikon: Further company coverage:",
        "date": "04272017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr. Reddy's Labs launches Ezetimibe and Simvastatin tablets in U.S. market "
    },
    {
        "content": "* Dr.Reddy's Laboratories - announces the launch ofprogesterone capsules in the U.S. market\". Source text: (http://bit.ly/2pLTt0P) Further company coverage:",
        "date": "04212017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Laboratories announces launch of progesterone capsules in the U.S. "
    },
    {
        "content": "Dr. Reddy's Laboratories Ltd and three pharmacy chains have won the dismissal of a whistleblower lawsuit accusing them of fraudulently seeking federal reimbursement for drugs that were distributed in packaging not tested for child safety.",
        "date": "03282017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "Judge tosses drug packaging case against Dr. Reddy's  pharmacies "
    },
    {
        "content": "* Co  Integra Lifesciences enter agreement to market  distribute Duragen plus and suturable duragen dural regeneration in India",
        "date": "03272017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr. Reddy's Labs  Integra Lifesciences sign deal to market Duragen products in India "
    },
    {
        "content": "* Have entered into a partnership with Dr. Reddy's laboratories ltd for South African market",
        "date": "03162017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Cytosorbents Corp enters into a partnership with Dr. Reddy's laboratories "
    },
    {
        "content": "* Says the audit of API manufacturing plant at Miryalaguda  by the US FDA  has been completed on February 21  2017",
        "date": "02212017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Labs gets form 483 with 3 observations from USFDA for audit of Miryalaguda plant "
    },
    {
        "content": "* Clarifies on news item \"Dr. Reddy's announces US district court's opinion relating to patent infringement\"",
        "date": "02172017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Labs says no claims against co for monetary damages "
    },
    {
        "content": "* Says Dr. Reddy's Laboratories announces U.S. district court's opinion relating to patent infringement",
        "date": "02162017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr Reddy's says U.S. court finds co's product infringes some patents "
    },
    {
        "content": "* Dr.Reddy's Laboratories clarifies on news item \"Korean biotech firm Mezzion Pharma files suit against Dr Reddy's laboratories.\"",
        "date": "01272017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Labs says co not served with legal papers in matter as in Mezzion's press release "
    },
    {
        "content": "* Clarifies on news item \"FDA to re-audit three Dr.Reddy's labs plants\"",
        "date": "01122017",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr. Reddy's Labs says U.S. FDA re-audit of co's plants part of \"usual activity\" "
    },
    {
        "content": "* Announces the launch of Raloxifene HCI tablets  USP in the U.S. Market  Source text: http://bit.ly/2fHr5V4 Further company coverage:",
        "date": "11112016",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Laboratories announces launch of Raloxifene HCI tablets in the U.S. "
    },
    {
        "content": "* Sucampo pharmaceuticals inc - company raises 2016 guidance and provides preliminary 2017 guidance",
        "date": "11092016",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Sucampo Q3 adjusted EPS $0.28 "
    },
    {
        "content": "* Exec says have addressed all FDA requirements on warning letters",
        "date": "10252016",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Labs exec says co has addressed all FDA requirements on warning letters "
    },
    {
        "content": "* Co to continue to focus on launching new products in generic business",
        "date": "10252016",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "normal",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Laboratories Sept-qtr consol profit falls 60 pct "
    },
    {
        "content": "* Dr. Reddy's Laboratories announces the launch of Aripiprazole tablets  USP tablets in the U.S. market  Source text for Eikon:  Further company coverage:    (Bengaluru newsroom)",
        "date": "10132016",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr. Reddy's Labs launches Aripiprazole tablets  USP tablets in U.S. market "
    },
    {
        "content": "* Announces the launch of Lamotrigine Orally Disintegrating tablets in the U.S. market  Source text: http://bit.ly/2dFkVt2 Further company coverage:",
        "date": "10102016",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's launches Lamotrigine Orally Disintegrating tablets in U.S "
    },
    {
        "content": "* Announces entry into Columbia  Source text: http://bit.ly/2dzOUiD Further company coverage:    (Bengaluru newsroom)",
        "date": "10072016",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Dr.Reddy's Labs announces entry into Columbia "
    },
    {
        "content": "* Launch of bupropion hcl extended-release tablets  usp (sr) in u.s. Market  Source text for Eikon:  Further company coverage:",
        "date": "09022016",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-DR. Reddy's laboratories says launch of Bupropion HCL extended-release tablets  USP (sr) in U.S. market "
    },
    {
        "content": "* Co's unit  dr. Reddy's labs  ltd entered into settlement agreement to resolve their patent litigation relating to folotyn",
        "date": "05312016",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "BRIEF-Spectrum Pharma says Dr Reddy's will be permitted to market generic version of Folotyn in US on Dec 1  2022 or earlier "
    },
    {
        "content": "MUMBAI  March 10 Indian drugmaker Dr.Reddy's Laboratories Ltd is in talks to acquire the Indian operations of Belgian pharmaceutical company UCB SA for about $135 million  said a person with direct knowledge of the matter.",
        "date": "03102015",
        "name": "Dr Reddy&#39;s Laboratories Ltd",
        "news_type": "topStory",
        "symbol": "RDY",
        "title": "Dr.Reddy's in talks to buy UCB India business for $135 mln - source "
    }
]